MedTrace Logo

A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects

NCT05031624 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2022-01-21

No results posted yet for this study

Summary

This is a study to determine the safety and pharmacokinetics of CDX-0159 administered subcutaneously in healthy subjects.

Conditions

  • Healthy Subjects

Interventions

DRUG

CDX-0159

Single subcutaneous dose of one of four dosages of CDX-0159

DRUG

Normal saline

Single subcutaneous dose of normal saline

Sponsors & Collaborators

  • Celldex Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-30
Primary Completion
2022-01-14
Completion
2022-01-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05031624 on ClinicalTrials.gov